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Abstract
Background: Parkinson’s disease (PD) is a motor disease associated with the degeneration of dopaminergic
neurons of the substantia nigra pars compacta. p53 is a major neuronal pro-apoptotic factor that is at the center of
gravity of multiple physiological and pathological cascades, some of which implying several key PD-linked proteins.
Since p53 is up-regulated in PD-affected brain, we have examined its ability to regulate the transcription of
α-synuclein, a key protein that accumulates in PD-related Lewy bodies.
Results: We show that pharmacological and genetic up-regulation of p53 expression lead to a strong increase of
α-synuclein protein, promoter activity and mRNA levels. Several lines of evidence indicate that this transcriptional
control is due to the DNA-binding properties of p53. Firstly, p53 DNA-binding dead mutations abolish p53
regulation of α-synuclein. Secondly, the deletion of p53 responsive element from α-synuclein promoter abrogates
p53-mediated α-synuclein regulation. Thirdly, gel shift and chromatin immunoprecipitation studies indicate that p53
interacts physically with α-synuclein promoter both in vitro and in a physiological context. Furthermore, we show
that the depletion of endogenous p53 in cells as well as in knockout mice down-regulates α-synuclein
transcription.
Conclusions: Overall, we have identified α-synuclein as a new transcriptional target of p53 and delineated a cellular
mechanism feeding the accumulation of toxic aggregated α-synuclein in PD. This original α-syn regulatory
mechanism may be central to PD-related cell death and may lead to novel opportunities to design alternative
neuroprotective strategies in PD.
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Background
Parkinson’s disease (PD) is a major age-related motor
disease in which several causative genes have been iden-
tified. Amongst these genes, α-synuclein (α-syn) has
caught a special attention given its important role in PD
etiology [1, 2]. Thus, α-syn is a small phosphoprotein,
that accumulates in intracellular inclusions named Lewy
bodies in most of sporadic and genetic PD cases [3]. We
previously showed that it exerts an anti-apoptotic pheno-
type by down-regulating p53 expression and transcrip-
tional activity in neuronal cells [4, 5]. Importantly this
neuroprotective phenotype can be abrogated by various
processes leading to its accumulation and/or aggregation.
Thus, we have shown that 6-hydroxydopamine, an en-
dogenously produced dopamine catabolite frequently used
to trigger PD ex-vivo and in vivo, leads to α-syn
aggregation and consequently, abolishes α-syn ability to
repress p53 [6].
It is interesting to note that several proteins such as
DJ-1 and parkin, which when mutated trigger familial
forms of PD, have been shown to regulate and, to be
regulated by p53 [7–11]. In this context, the ability of α-
syn to regulate p53 led us to postulate that p53 could
also control α-syn levels as part of a feedback process
driving their cellular homeostasis in neurons. Given the
canonical transcription factor properties of p53, we have
examined the putative p53-dependent control of α-syn
transcription in a pathophysiological context. Our study
demonstrates that both selective pharmacological treat-
ments and genetic manipulation of p53 by overexpres-
sion or invalidation approaches trigger a modulation of
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α-syn transcription by a mechanism implying the phys-
ical interaction of p53 with α-syn promoter. Thus, the
deletion of putative p53 responsive element of α-syn
mouse promoter leads to full abolishment of p53-mediated
α-syn transcription up-regulation. ChIP (chromatin immu-
noprecipitation) and gel shift analyses demonstrate that the
p53 and α-syn interaction occurs in physiological context
in absence of any transcription co-factor. Importantly, ana-
lysis of α-syn protein and mRNA levels in p53 knockout
mouse brain further documents the transcriptional control
of α-syn by p53 in vivo. Overall, our data identify α-syn as
a novel p53 transcriptional target and thus, delineate a
functional interplay driving their cellular homeostasis. Our
study pinpoints to the fact that the disruption of this cellu-
lar dialogue linked to the dysfunction of any of these two
partners may contribute to PD pathology.
Results
Pharmacological manipulation of p53 affects α-syn
transcription
p53-associated transcriptional function can be activated
by several pharmacological compounds, either triggering
post-transcriptional protein stabilization through enhanced
phosphorylation (etoposide, ETO) or favoring its nuclear
localization (leptomycin B, LM) where it is protected from
proteasome-driven degradation [12]. p53 activity can also
be activated by physical treatment such as ultra violet (UV)
irradiation. We took advantage of this range of cellular
challenges to examine whether p53 modulation could
indeed influence α-syn mRNA and protein levels in the
SH-SY5Y dopaminergic neuroblastoma cell line. As ex-
pected, all pharmacological treatment (12 hours) and phys-
ical challenges (see Methods section) trigger enhanced
expression of p53 (Fig. 1a-c, upper panels). Interest-
ingly, they concomitantly increase both α-syn protein
(ETO, +95.7 % ± 29 of control untreated cells, n = 6,
Fig. 1a; LM, +48.5 % ± 8.5, n = 9, Fig. 1b; UV, +63 %
± 22.8, n = 7, Fig. 1c) and mRNA (ETO, +97.8 % ±
23.3, n = 6, Fig. 1d; LM, +51.9 % ± 7.3, n = 9, Fig. 1e; UV,
+59.7 % ± 15.7, n = 7, Fig. 1f) levels.
Overexpressed and endogenous p53 control α-synuclein
transcription in cells and in mouse brain
We have examined the influence of ectopic and en-
dogenous p53 on α-syn protein and mRNA levels as well
as on α-syn mouse promoter-linked luciferase activity
(see Methods). Thus, as showed in Fig. 2 (panels a-d) 24
hours post-transfection, transiently overexpressed p53 in
SH-SY5Y cells (see Fig. 2a) triggers an up-regulation of
α-syn protein expression (+51.2 % ± 18.9, n = 9, Fig. 2a
and b) and mouse wild-type full length α-syn promoter
transactivation measured as above (+478.2 % ± 54.8, n = 12,
Fig. 1 Effects of UV irradiation and pharmacological activation of p53 on α-syn protein and mRNA levels. SH-SY5Y cells were treated with vehicle
(Ct) or with etoposide (ETO, 150 μM, a and d) leptomycin (LM, 10 nM, b and e) and UV irradiation (UV, c and f) then α-syn protein (a-c) and
mRNA levels (d-f) were analyzed as described in the Methods section. p53 and actin immunoreactivities are provided as read-out of p53
activation and gel loading controls respectively (a-c, upper panels). Bars represent the means ± SEM of 3 independent experiments performed in
duplicates and are expressed as percentage of vehicle-treated or non-irradiated control cells. Statistical analyses were performed with GraphPad
Prism software (www.graphpad.com version 4.00 for Windows, San Diego, California USA) by using homoscedastic, unpaired Student’s t-test.
Significant differences are: *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 2c) and mRNA levels (+41.8 % ± 10.2, n = 6, Fig. 2d).
We took advantage of a mouse embryonic fibroblast
(MEF) cell line devoid of both p53 and p19arf (p19arf-/-,
p53-/-) that we compared to its control p19arf-/- [13] to
examine the contribution of endogenous p53. As illus-
trated in Fig. 3a-d, p53 knockout cells (white bars) display
significant decreases of α-syn protein expression (-61.6 %
± 16.7, n = 9, Fig. 3a, b), mouse wild-type full length α-
syn promoter transactivation (luciferase assay, see
Methods) 24 hours post-transfection (-59.3 % ± 6.2, n =
12, Fig. 3c) and mRNA levels (-55.8 % ± 9.6, n = 6, Fig. 3d).
Interestingly, UV treatment increases α-syn protein and
mRNA levels in control p19arf-/- cells (+42.6 % ± 10.6, n =
6, Additional file 1: Figure S1A and +53.2 % ± 19.9, n = 9,
Additional file 1: Figure S1B, respectively) but not in fibro-
blasts lacking endogenous p53 (Additional file 1: Figure
S1A,B white bars). As a matter of confirmation of an
endogenous p53-dependent control of α-syn mRNA tran-
scription in cell lines of human origin, we used the human
colon carcinoma HCT116 (Fig. 3e-h) and haploid HAP1
(Additional file 2: Figure S2A-C) cells to compare the
parental cell lines that exhibit wild-type p53 (HCT+/+,
HAP+/+) to the ones in which p53 gene is disrupted
(HCT-/-, HAP-/-). Figure 3e-h shows that the full deple-
tion of endogenous p53 (see lack of expression in Fig. 3e)
also triggers a reduction of α-syn protein expression
(-73.2 % ± 11.2, n = 6, Fig. 3e,f ), mouse wild-type full
length α-syn promoter transactivation measured as
above 24 hours post-transfection (-86.4 % ± 6.3, n = 6,
Fig. 3g) and mRNA levels (-57.4 % ± 11.7, n = 6, Fig. 3h)
in HCT116 cells. Similar significant decreases of α-syn
protein expression (-44.2 % ± 8.0, n = 8, Additional file 2:
Figure S2A,B) and mRNA levels (-47.3 % ± 3.5, n = 6,
Fig. 2 Overexpressed p53 controls α-syn transcription. SH-SY5Y cells
transiently transfected with an empty vector (EV, black bars) or
wild-type p53 cDNA (p53, white bars) were assessed for α-syn
protein (a and b), promoter transactivation (c) and mRNA levels (d). Bars
in a-d represent the means ± SEM of 3-4 independent experiments
performed in duplicates or triplicates and are expressed as percentage
of control EV cells. Statistical analyses were performed with GraphPad
Prism software by using homoscedastic, unpaired Student’s t-test.
Significant differences are: **p< 0.01, and ****p < 0.0001
Fig. 3 Mouse and human endogenous p53 control α-syn transcription. Control mouse fibroblasts (MEF, p19arf-/-, black bars) or MEF devoid of p53
(p19arf-/- p53-/-, white bars) were assessed for α-syn protein (a and b), promoter transactivation (c) and mRNA levels (d) in basal conditions as
described in the Methods section. α-syn protein (e, f), promoter transactivation (g) and mRNA levels (h) were analyzed in HCT116 control (HCT+/+,
black bars) or p53-deficient (HCT-/-, white bars) cells as described in the Methods section. Bars in A-D represent the means ± SEM of 3-4 independent
experiments performed in duplicates or triplicates and are expressed as percentage of control p19arf-/- (a-d) or HCT+/+ (e-h) cells. Actin expression is
provided as a gel loading control in (a, e). Statistical analyses were performed with GraphPad Prism software by using homoscedastic, unpaired
Student’s t-test. Significant differences are: **p < 0.01, and ***p < 0.001
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Additional file 2: Figure S2C) were observed in
HAP -/- cells.
In order to establish that our ex-vivo observations also
stand in vivo, we have compared α-syn protein (left
brain hemisphere) and mRNA status (right brain hemi-
sphere) of wild-type mouse harboring (p53+/+) or lacking
(p53-/-) endogenous p53. p53 knockout mouse brains
show a similar reduction of α-syn protein expression
(-58.9 % ± 11.6, n = 6, Fig. 4a) and mRNA levels (-51.8 % ±
10.1, n = 9, Fig. 4b). Overall, the above-described data
demonstrate that pharmacological modulation or genetic
manipulation of endogenous p53 control α-syn mRNA
transcription and protein levels in various cell types from
both murine and human origin as well as in mouse brain.
p53 DNA-binding dead-mutations abolish α-synuclein
transcriptional regulation ex-vivo
In order to establish if the transcriptional regulation of
α-syn was associated to the DNA-binding properties of
p53 underlying its transcription factor activity, we have
analyzed the impact of two p53 mutations (R273H and
R248W) known to disrupt this function. These ex-
tremely frequent (hot spot) cancer-related p53 mutations
were selected due their extensive characterization re-
garding their impact to p53 DNA-binding properties
[14, 15]. As expected, Fig. 5 first confirms that the
overexpression of wild-type p53 in SH-SY5Y cells (see
expression in Fig. 5a, upper panel) increases α-syn pro-
tein expression (+49.8 % ± 15.3, n = 12, Fig. 5a), mouse
wild-type full length α-syn promoter transactivation
measured by means of the luciferase reporter gene activ-
ity assay (+76.1 % ± 17.1, n = 9, Fig. 5b) and mRNA levels
(+39 % ± 9.6, n = 6, Fig. 5c). However, while transient
cDNA transfections of wild-type and mutated p53 led to
very similar p53 expressions (Fig. 5a, upper panel), both
mutations impair p53 ability to up-regulate α-syn
protein expression (Fig. 5a), promoter transactivation
(Fig. 5b) and mRNA levels (Fig. 5c).
α-syn is a direct p53 transcriptional target
The question arose as to whether p53 could directly or
indirectly modulate α-syn promoter transactivation. An
in silico bioinformatic search for p53 DNA-binding con-
sensus motif [16] identified a unique motif correspond-
ing to half of the canonical p53 responsive element in
the mouse α-syn promoter (-970→ -967, Fig. 6a). We
first examined the influence of the deletion of this puta-
tive p53 responsive element on p53-mediated modula-
tion of α-syn transcription. First, as expected, we
confirmed that, conversely to the phenotype observed
after depletion of endogenous p53, its overexpression
(see Fig. 6b, upper panel) increases α-syn wild-type full
length α-syn mouse promoter transactivation (+123.1 %
± 16.6, n = 12, Fig. 6b compare black bars). This p53-
related phenotype is completely abolished by the re-
moval of the p53-binding domain on the α-syn promoter
construct (Δ α-syn prom., Fig. 6b, compare white bars).
Two lines of additional data definitely flag-up α-syn as a
transcriptional target of p53. Firstly, we performed elec-
trophoretic mobility shift assay (EMSA) where recom-
binant wild-type p53 protein and biotinylated α-syn-
derived probe encompassing its p53 DNA-binding motif
were incubated together. This bi-molecular reaction al-
lows monitoring a genuine physical interaction between
the two partners in absence of any cellular modulator or
intermediate. Figure 6c illustrates the gel shift elicited by
p53/α-syn probe physical interaction (Fig. 6c, compare
lanes 1 and 2). The specificity of this interaction was
demonstrated by its blockade by pre-incubation of p53
recombinant protein with two distinct p53 antibodies
pab421/DO1 (anti-p53, lane 3 and 6 respectively) or by
incubation with an excess of specific non-biotinylated α-
syn probes (comp-sp, lanes 4 and 5). Secondly, we
showed by ChIP experiments that endogenous p53 im-
munoprecipitation yielded a α-syn promoter PCR-
amplified fragment containing the p53 DNA-binding
motif (Fig. 6d, compare control lane 2 with IPed lane 3).
This set of deletion-based analysis, gel shift data and
ChIP experiments all support our in silico prediction
and demonstrate that α-synuclein behaves as a genuine
direct p53 transcriptional target.
Discussion
p53 is a transcription factor, which main physiological
function is to regulate genes involved in the control of
cell cycle, DNA repair and apoptosis [17, 18]. Thus, p53-
associated gene modulation normally stops cell growth
Fig. 4 p53 control α-syn transcription in vivo. Analyses of α-syn
protein (a) and mRNA levels (b) in control (p53+/+, black bars) or
TP53 gene invalidated (p53-/-, white bars) mouse brain as described
in the Methods section. Bars represent the means ± SEM of n = 6 (a)
or n = 9 animals (b) and are expressed as percentage of control
p53+/+ mouse brain samples. Actin expression (a) is provided as
protein loading control. Statistical analyses were performed with
GraphPad Prism software by using homoscedastic, unpaired Student’s
t-test. Significant differences are: **p < 0.01, and ***p < 0.001
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by blocking the cell cycle at the G1/S phase and triggers
a pro-apoptotic cascade [18]. Moreover, p53 is a pro-
apoptotic protein strongly linked to several neuro-
degenerative disorders, amongst which Parkinson’s
disease [19]. Thus, post-mortem studies of PD-affected
patients have shown abnormal p53 expression and the
evaluation of the impact of toxin-induced PD demon-
strated a strong contribution of p53 in dopaminergic
cell death. Finally, several PD-causative gene products
including DJ-1 and parkin, have been shown to
Fig. 5 Effect of mutated p53-mediated α-syn regulation ex-vivo. α-Synuclein protein (a), promoter transactivation (b) and mRNA levels (c) were
analyzed after transient overexpression of empty pcDNA3.1 vector (EV, black bars) or vectors encoding for wild-type p53 (p53, white bars), R248W
or R273H mutants of p53 (248 and 273, gray bars) in SH-SY5Y cells as described in the Methods section. Representative gels of p53 (flag) and actin
immunoreactivities (a) are provided to illustrate transfection efficiency and control of gel loading, respectively. Bars represent the means ± SEM
of 3 independent experiments performed in duplicates (a, c) or triplicates (b) and are expressed as percent of EV- transfected cells. Statistical
analyses were performed with GraphPad Prism software by using One-way ANOVA analysis of variance coupled to a Newman Keuls post-hoc test.
Significant differences are: **p < 0.01, and ***p < 0.001
Fig. 6 p53 interacts physically with murine α-syn promoter. a Scheme of the region of wild-type α-synuclein promoter (WT α-syn prom) with the
p53 DNA-binding motif indicated in bold. The -970-967 (5’-CATG-3’) region underlined has been deleted (Δα-syn prom). b SH-SY5Y cells were
co-transfected with either empty pcDNA3 vector (EV, lanes -) or p53 cDNA (p53, lanes +) and WT α-syn prom (black bars) or Δα-syn prom
(empty bars) constructs then promoter activities were measured as described in the Methods section. p53 expression was controlled by anti-Flag
antibodies as described in Methods. Bars represent the means ± SEM of 4 independent experiments performed in triplicates and are expressed as
percentage of control EV-transfected cells. c EMSA analysis of the interaction of wild-type recombinant p53 (p53r) with α-syn-derived biotinylated
probe encompassing the consensus sequence shown in (a). Reactions were carried out in absence (-) or in the presence (+) of either an excess
of specific cold probes (comp-sp, see lanes 4, 5) or p53-directed antibodies (anti-p53 pab421/DO1, lanes 3, 6) and analyzed as described in the
Methods. Free probe control is shown in lane 1. d ChIP analysis of the interaction between endogenous p53 with α-syn endogenous promoter in
MEF cells by endpoint semi-quantitative PCR (upper gel) or real time PCR (histogram) as described in Methods. In (d), lanes 1–5 correspond to
100 bp DNA ladder (STD), normal mouse IgG ChIP (CT), p53 ChIP (IP), input (INP) and no template control (H2O), respectively. Statistical analysis
was performed with GraphPad Prism software by using either One-way ANOVA analysis of variance coupled to a Newman Keuls post-hoc test
(b) or homoscedastic, unpaired Student’s t-test (d). Significant differences are: *p < 0.05, ***p < 0.001, and ns for non-significant
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control and to be controlled by p53 ex-vivo and in
vivo [19, 20].
Our study unravels for the first time α-syn as an add-
itional transcriptional target of p53. This conclusion
stands on five independent lines of data. Firstly, overex-
pression of p53 or its pharmacological activation en-
hance α-syn promoter activity, mRNA and protein levels
in human and murine cells from various origins while
p53 gene depletion triggers the opposite phenotype in
cells as well as in vivo, in mouse brain; secondly, DNA-
binding dead mutations of p53 abolish p53-induced α-syn
transactivation both ex-vivo; thirdly, the deletion of a pu-
tative p53 DNA-binding element on the α-syn promoter
prevents p53-mediated increase of α-syn promoter activa-
tion; fourth, EMSA experiments indicated that recombin-
ant p53 and α-syn promoter-derived probes physically
interact directly without the need of any cofactor; fifthly,
ChIP analysis demonstrates the physical association of en-
dogenous p53 with α-syn promoter in an ex-vivo physio-
logical context.
Very few works aimed at studying the transcriptional
regulation of α-syn have been performed. Importantly,
previous data indicated that α-syn mRNA levels could
be modulated by PD inducers like MPTP (1-Methyl-4-
phenyl-1,2,3,6-tetrahydropyridine hydrochloride) [21] and
appeared increased in PD-affected brains [22]. Thus, our
data allowed the establishment of a molecular mechanism
that ultimately may contribute to the transcriptional
modulation of α-syn in sporadic PD.
We previously established that α-syn lowers both p53
protein levels and transcriptional activity in neuronal
cell lines [5] and that this control was abolished by
6-hydroxydopamine that triggers both α-syn oxidation
and aggregation and proteasomal inhibition [6]. This
study, together with our present data, unravels a func-
tional interplay between α-syn and p53 that could be
disrupted in pathological conditions. Thus, in normal con-
ditions, α-syn represses p53 [1, 5]. This reduction of p53
triggers lowering of α-synuclein transactivation and pro-
tein levels (present study), which in turn restores p53
physiological levels. We speculate that this reciprocal
physiological control, which allows the homeostasis of
both proteins, may be impaired in PD due to dysfunctions
of either α-syn or p53. Thus, in those cases where the
function of α-syn is hampered by its aggregation or by
pathogenic mutations, one can anticipate the accumula-
tion of p53 and by consequence the establishment of a
deleterious p53-mediated transcriptional feeding of α-syn
increase. Alternatively, since p53 is at the crossroad of
multiple signaling cascades involved in PD pathogenesis,
one can suppose that its abnormal activation could lead to
excessive α-syn transcription and production. Since α-syn
aggregation is strongly linked to its protein levels, one can
envision that p53 could contribute to α-syn
aggregation and toxicity via exacerbation of its tran-
scriptional regulation.
Conclusions
Our work demonstrates that α-syn promoter harbors
a functional p53 responsive element. Thus, p53 inter-
acts with the mouse α-syn promoter and up-regulates
α-syn transcription. Pharmacological and genetic ma-
nipulation of p53 impacts α-syn regulation and im-
portantly, endogenous p53 regulates α-syn transcription
ex-vivo and in vivo. This first delineation of α-syn as a
physiological transcriptional target of p53 unraveling a
functional dialogue between these two proteins allows
proposing that, in a PD-linked pathological context, α-syn
toxicity could be likely the consequence of a loss of its
physiological interplay with p53.
Methods
Cellular and animal models
Mouse Embryonic Fibroblasts (MEF), Human Colorectal
adenocarcinoma (HCT116), SH-SY5Y human neuroblast-
oma, cell lines were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10 % fetal
calf serum, penicillin (100 U/ml) and streptomycin (50 μg/
ml) and incubated at 37 °C in a 5 % CO2 atmosphere.
HAP1 cells purchased from Horizon Genomics (HAP1
p53+/+) is a haploid human cell line that was derived from
KBM-7 cells (see [23] HAP1 clone 1068-1 (HAP1 p53-/-)
was engineered using CRISPR/cas9 and contains one base
insertion in exon 6 leading to a frame-shift in TP53 coding
sequence. HAP1 cells were cultured in Iscove’s Modified
Dulbecco’s Medium (IMDM) with 10 % fetal calf serum,
penicillin (100 U/ml) and streptomycin (50 μg/ml). Im-
mortalized mouse embryonic fibroblasts invalidated for
p53 or for p53 and p19arf genes were kindly provided
by Drs. M. Roussel (St. Jude Children’s Research Hospital
Memphis, TN, USA) whereas the cell lines HCT116 inva-
lidated or not for p53 were provided by J.C. Bourdon
(University of Dundee, Dundee, UK). p53 knockout
mice have been provided by Dr. M. Serrano (Spanish
National Cancer Research Center, Madrid, Spain).
Pharmacological and UV irradiation-mediated modulation
of p53
Activation of p53 was achieved by UV-light irradiation
of the cells by means of a cross-linker apparatus (254
nm bulb). Various cell types were cultivated in 35 mm
dishes and submitted to a double optimal crosslink
treatment (60 sec, 120 mJ/cm2) when they reached 80 %
confluence then left 24 hours at 37 °C in a 5 % CO2
atmosphere. The pharmacological modulation of p53
was obtained after 12 hours incubations with etoposide
(150 μM) or leptomycin (10 nM). After treatments, cells
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were recovered and protein and RNA analyses were
monitored as described below.
Western-blot protein analysis
α-syn, p53 and actin expressions were analyzed in various
cell lines and mouse brain homogenates (50-200 μg of
proteins) then loaded on 12-16 % sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
gels and wet-transferred to Hybond-C (Amersham Life
Science) membranes. Transferred proteins were immuno-
blotted using anti-α-syn (#2642, Cell Signaling), anti-flag
(clone M2, F3165, Sigma), anti-p53 (CM1, provided by
J.C. Bourdon) and anti-actin (clone AC-74, A5316, Sigma)
antibodies. Immunological complexes were revealed with
either anti-rabbit or anti-mouse IgG-coupled peroxidase
antibodies (Jackson ImmunoResearch) by the electro-
chemiluminescence detection method (Roche Diagnostics
S.A.S). Chemiluminescence was recorded using a lumines-
cence image analyzer LAS-4000 (Raytest, Fuji) and quanti-
fications of non-saturated images were performed with
the FUJI Film Multi Gauge image analyzer software.
Plasmid constructs and transfections approaches
The generation of wild-type and R273H flag-tagged p53
mutant of human p53 flag-tagged coding sequences in
the mammalian expression vector pcDNA3.1 (+) has
been extensively described [24]. To generate the R248W
p53 mutant, we used the site‐directed mutagenesis kit
from Stratagene along with the forward p53R248WS
(5’-GGG-CGG-CAT-GAA-CTG-GAG-GCC-CAT-CCT-
CAC-C-3’) and the reverse p53R248WAS (5’-GGT-
GAG-GAT-GGG-CCT-CCA-GTT-CAT-GCC-GCC-C-3’)
primers.
To clone the mouse SNCA promoter, 200 ng of mouse
fibroblast genomic DNA, obtained using the kit QIAamp
DNA mini kit (Qiagen) were added to a high fidelity PCR
reaction mix, with forward primer 5’-CGA-CGC-GTG-
GAG-GAG-CTT-GGC-ACT-CAA-ATC-3’ containing a
MluI restriction site and the reverse primer 5′-GAA-GAT-
CTG-GCT-AAA-GAT-GTA-TTT-TTG-CTC-CAC-ACT-
AG-3′ containing a BglII restriction site. The 2251 nucle-
otides amplicon (DNA fragment immediately upstream
the translation initiation codon of mouse SNCA gene) has
been cloned between the MluI and BglII sites of the pGL3
basic vector (containing the sequence coding for lucifer-
ase) from Promega. This pGL3 vector containing the
mouse SNCA promoter served as a template to generate
the promoter deleted of the 5’-CATG-3’ nucleotides
that constitute part of the p53 putative binding site.
The primers used were 5′-CTT-TCC-TTT-CGC-TGG-
AGA-CCC-TTC-CAT-CCT-GTC-3′ (forward primer) and
5′-GAC-AGG-ATG-GAA-GGG-TCT-CCA-GCG-AAA-
GGA-AAG-3′ (reverse primer). All the constructs were
verified by full sequencing. Transient transfections of
SH-SY5Y and HAP1 cells were carried out by means
of lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions.
Luciferase-based reporter assays
The transactivation of the wild-type and mutated SNCA
mouse promoter described in the plasmid constructs
section was followed by recording the luciferase reporter
gene activity 24 hours after co-transfection of 0,5–1 μg
of the above cDNAs and 0,2–0,5 μg of β-galactosidase
cDNA (in order to normalize for transfection efficiencies)
by means of lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions (Invitrogen). When
necessary, in a subset of experiments, 0,5–1 μg of
empty pcDNA3.1, wild type or mutated p53 were co-
transfected.
RNA extraction, reverse transcription and real-time PCR
analysis
RNA from cells and RNA later (Qiagen) stabilized
mouse brains (right hemisphere) were extracted and
treated with DNAse using RNeasy or RNeasy Plus Uni-
versal Mini kits respectively following manufacturer’s
instructions (Qiagen). Two μg of total RNA were reverse
transcribed (GoScript Reverse Transcriptase, Promega)
using Oligo-dT priming. Then, samples were subjected
to real-time PCR by means of a Rotor-Gene 6000 appar-
atus (Qiagen), using the SYBR Green detection protocol.
Gene-specific primers were designed with the Universal
Probe Library Assay Design Center software (Roche





amplification products were normalized for RNA concen-
trations by mouse γ-actin (forward: 5′-CAC-CAT-CGG-
TTG-TTA-GTT-GCC-3′; reverse: 5′-CAG-GTG-TCG-
ATG-CAA-ACG-TT-3′) or human GAPDH (forward:
5′-TGG-GCT-ACA-CTG-AGC-ACC-AG-3′; reverse: 5′-
CAG-CGT-CAA-AGG-TG G-AGG-AG-3′) mRNA ex-
pression levels.
Electrophoretic mobility gel shift assay (EMSA)
EMSA was performed by means of a commercial Gel
shift Chemiluminescent EMSA Assay Kit provided by
Active Motif. In brief, purified wild-type p53 recombin-
ant protein (200 ng; SC4246, Santa Cruz) was incubated
in 1X binding buffer (Promega) containing 100 ng poly
(dI-dC), dithiothreitol (10 mM) and Bovine Serum
Albumin (1 mg/ml) at 4 °C for 30 min with 20 fmol of
double stranded 5’ biotin end-labeled SNCA-derived
oligonucleotides (forward: 5′-CCT-TTC-GCT-GGA-GAC-
ATG-CCC-TTC-CAT-CCT-GTC-AAA-GCC-C-3′; reverse:
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5′-GGG-CTT-TGA-CAG-GAT-GGA-AGG-GCA-TGT-
CTC-CAG-CGA-AAG-G-3′) encompassing the putative
p53 responsive element. Protein-probe complexes were then
resolved by electrophoresis on a 5 % native polyacrylamide
gel at 4 °C, transferred to a positively charged nylon mem-
brane (Thermo Scientific), cross-linked (UV-light cross-
linker equipped with a 254 nm bulb) and revealed by
means of streptavidin conjugated to horseradish pero-
xidase (HRP) and a chemiluminescent substrate. When
indicated, in order to confirm specific DNA-protein inter-
action, we performed a 15–30 min pre-incubation at 4 °C
with either an excess (4 pmol) of unlabeled specific and
non-related control DNA or pab421 before adding the
biotin-labeled probes.
Chromatin Immunoprecipitation assay (ChIP)
ChIP assay was performed according to EZ- ChIP kit in-
structions (Millipore). Briefly, 107 cells were fixed with
formaldehyde (1 % final concentration), treated with gly-
cine to quench unreacted formaldehyde and recovered
in cold phosphate buffered saline (PBS) containing the
protease inhibitor cocktail II. Pelleted cells were lysed in
the SDS lysing buffer and sonicated on ice in order to
obtain chromatin fragments of about 200-500 bp in size.
After a preclearing step using protein G Agarose, im-
munoprecipitation was performed either with anti-p53
primary antibody (pab421, Enzo Life Sciences) or normal
mouse IgG as a negative control. Immunocomplexes
were then incubated with a solution of protein G-
agarose. After elution of the immunocomplexes from
beads, crosslinks were reversed and RNA and protein
eliminated by RNAse and proteinase K treatments. DNA
was purified and subjected to a standard end-point
and real-time PCR using primers (forward: 5′-CGC-
CTA-GAG-AAG-ACC-AAC-TAC-AGC-TGC-3′; reverse:
5′-GCA-CTA-AGC-TTC-CAC-CAT-CCA-GCA-CTC-
AAC-3′) specific for the -1061/-852 DNA region (210
bases-long amplicon) upstream the start codon of mouse
SNCA gene. We calculated the enrichment as the ratio of
the amplification efficiency of the ChIP sample over that
of the IgG.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism software (www.graphpad.com version 4.00 for
Windows, San Diego, California USA). All groups of
samples analyzed by Student’s t-test have passed a
normality test to assure Gaussian distribution of
values and precision concerning the type of test (un-
paired versus paired and homoscedastic versus hetero-
scedastic) are provides in figures legends. Analysis of
more than two groups of variables (normality test
passed) was performed by One-way ANOVA with
Newman-Keuls’s post-hoc test. Significant differences
are: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 and
ns = non significant.
Additional files
Additional file 1: UV-induced increase of a-syn expression is
abolished by TP53 invalidation in MEF cells. Control (MEF, p19arf-/-,
black bars) or p53-deficient (p19arf-/-, p53-/-, white bars) mouse fibroblasts
were assessed for α-syn protein (A) and mRNA levels (B) in basal conditions
(Ct) or after UV-treatment (UV) as described in the Methods section. Bars
represent the means ± SEM of 3-4 independent experiments performed in
triplicates (A) or duplicates (B) and are expressed as percentage of control
p19arf-/- cells. Actin expression (A) is provided as protein loading control.
Statistical analyses were performed with GraphPad Prism software by using
One-way ANOVA analysis of variance coupled to a Newman Keuls post-hoc
test. Significant differences are: *p < 0.05, ***p < 0.001, and ns for
non-significant. (JPG 196 kb)
Additional file 2: Influence of endogenous human TP53 invalidation
on α-syn regulation in human cells. α-syn protein (A, B) and mRNA
levels (C) were analyzed in HAP1 control (HAP+/+, black bars) or p53-deficient
(HAP-/-, white bars) cells as described in the Methods section. Bars represent
the means ± SEM of 3 independent experiments performed in duplicates and
are expressed as percent of control HAP1 (HAP+/+) cells. Actin expression is
provided as a gel loading control in (A). Statistical analyses were performed
with GraphPad Prism software (www.graphpad.com version 4.00 for
Windows, San Diego, California USA) by using homoscedastic, unpaired
Student’s t-test. Significant differences are: ***p < 0.001. (JPG 161 kb)
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modified Eagle’s medium; EMSA: electrophoretic mobility gel shift
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polyacrylamide gel electrophoresis; UV: ultra-violet; α-syn: α-synuclein.
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